Tigo Energy Delivers 30% More Energy for Dutch Residential Photovoltaic Solar System
Tigo Energy, Inc., the solar industry’s leading Flex MLPE (Module Level Power Electronics) supplier, today revealed that one of the Company’s solar systems in the Netherlands consistently produces 30% more energy by using Tigo MLPE Optimizers. The drastic increase in energy production was measured on a per-module basis by the Tigo EI software using the exclusive Reclaimed Energy feature. Solar installers planning to attend Solar Solutions International 2022 in Vijfhuizen are invited to meet with Tigo representatives to discuss hardware and software solutions like those used in this installation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406005028/en/
Five-orientation solar rooftop in the Netherlands which consistently produces 30% more energy by using Tigo MLPE Optimizers. (Photos courtesy of homeowner, energy consultant de Git of NL HDG Energie Advies)
The 12kWp solar system was designed and installed by homeowner Hans de Git, an energy consultant at NL HDG Energie Advies. The array spans five different roof orientations on the residence in North Holland and combines Tigo TS4-A-O optimizers with a Cloud Connect Advanced (CCA) datalogger and Tigo Access Point (TAP) antennas to enable rapid shutdown, module-level visibility, and Reclaimed Energy optimization. This universal system architecture is powered by Tigo EI software and eliminates the complications of mismatches caused by varied module orientations as well as variations in module output and inverter characteristics. Over the last two years, the system has generated 5MWh of clean energy, of which 1.5MWh represented reclaimed energy provided by the Tigo TS4-A-O optimizers.
“We started using Tigo in 2012, and we have become great fans of the Tigo family of solar MLPE optimizers because they bring benefits to us as the installer and our customers,” said Mr. de Git. “When it came time to choose equipment for a new PV installation on my own house, I didn’t hesitate to choose Tigo again. Because of the specific layout of the array, I would have needed at least five MPPTs to make it work properly, which would have meant adding at least one more inverter. With the Tigo TS4 platform, I avoided the expense of additional inverters, and I can now fully exploit the double MPP tracker of my string inverter.”
“Hearing about the success of Mr. de Git is what the solar industry is all about for me,” said Jaap van Kriekingen, business development manager for Benelux at Tigo Energy. “Tigo EI software provides a clear visual readout of energy production for homeowners, allowing them to see the benefits brought by optimization over time. This level of down-to-the-hour visualization provides the peace of mind that their PV systems are performing at their very best.”
Both Jaap van Kriekingen and Mirko Bindi, Tigo VP EMEA Sales and MD Europe, respectively, will be present at the Solar Solutions International at Expo Haarlemmermeer in Vijfhuizen, the Netherlands, from April 12-14, 2022 at IBC Solar B.V. booth nr B11.1. IBC Solar, which produces tailor-made solutions ranging from small residential PV plants to major solar projects in the Benelux region, will introduce its new AeroFix G3 mounting system at the expo.
To learn more about the Tigo TS4 platform and its exclusive Reclaimed Energy feature, read the latest case study or visit www.tigoenergy.com/ts4.
About Tigo Energy
Tigo Energy, the worldwide leader in Flex MLPE (Module Level Power Electronics), designs innovative solar power conversion and storage products that provide customers more choice and flexibility. The Tigo TS4 platform increases solar production, decreases operating costs, and enhances safety. When combined with the Tigo Energy Intelligence (EI) platform, it delivers module, system, and fleet-level insights to maximize solar performance and minimize operating costs. The Tigo EI Residential Solar Solution, a flexible solar-plus-storage solution for home installations, rounds out the Company’s portfolio of solar energy technology. Tigo was founded in Silicon Valley in 2007 to accelerate the adoption of solar energy, and its global team supports customers whose systems reliably produce gigawatt-hours of safe solar energy on seven continents. Find us online at www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005028/en/
Contact information
Gilberto Lembo
European Marketing Manager at Tigo Energy
marketing@tigoenergy.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde